1. Pathological response to neoadjuvant chemotherapy for muscle-invasive micropapillary bladder cancer.
- Author
-
Meeks JJ, Taylor JM, Matsushita K, Herr HW, Donat SM, Bochner BH, and Dalbagni G
- Subjects
- Aged, Aged, 80 and over, Carcinoma, Transitional Cell drug therapy, Carcinoma, Transitional Cell mortality, Chemotherapy, Adjuvant, Female, Follow-Up Studies, Humans, Male, Muscle Neoplasms mortality, Muscle Neoplasms pathology, Neoadjuvant Therapy, Neoplasm Invasiveness, New York epidemiology, Prospective Studies, Survival Rate trends, Treatment Outcome, Urinary Bladder Neoplasms drug therapy, Urinary Bladder Neoplasms mortality, Antineoplastic Agents therapeutic use, Carcinoma, Transitional Cell pathology, Muscle Neoplasms drug therapy, Urinary Bladder Neoplasms pathology
- Abstract
Objective: To describe the pathological outcomes of patients with muscle-invasive micropapillary bladder cancer who have undergone neoadjuvant chemotherapy., Patients and Methods: A total of 82 patients with muscle-invasive micropapillary bladder cancer were treated between 1997 and 2010. After excluding those with metastatic disease, micropapillary histology only at radical cystectomy (RC), and chemo-radiation as primary treatment, 44 patients remained. All patients had ≥cT2 disease before chemotherapy/surgery. The median follow-up after RC was 28 months. Neoadjuvant chemotherapy was initiated in 29 (66%) patients and all patients underwent RC (93%) or partial cystectomy (7%)., Results: Micropapillary histology was diagnosed at first transurethral resection in 37 (84%) patients. Final RC pathology revealed pT0 in 15 (34%) patients and positive lymph nodes in 13 (31%) patients. Down-staging to pT0 occurred in 13 (45%) of those who received neoadjuvant chemotherapy compared with two (13%) of those who did not (P = 0.049). Patients with pT0 disease with micropapillary histology had higher overall survival rates (25 vs. 92%) and lower rates of bladder cancer recurrence (21 vs. 79%) at the 24-month follow-up., Conclusions: Almost half of the patients responded completely to neoadjuvant chemotherapy with a pT0 rate of 45%; therefore, patients with the micropapillary variant of urothelial carcinoma should not be excluded from consideration for neoadjuvant chemotherapy., (© 2013 BJU International.)
- Published
- 2013
- Full Text
- View/download PDF